Magazine

Table: The Drug Front--the Battle Continues


Several other companies have targeted cancer therapies in development

Company (and Drug Name), Target and Status:

Abbott Laboratories (ABT-627)

Endothelin-A growth factor, in Phase 3 trials for prostate cancer

AstraZeneca (IRESSA)

An enzyme released by the EGF receptor, Phase 3 trial for lung cancer

Cell Genesys (GVAX)

Vaccine uses patient's tumor cells to stimulate immune system, Phase 2 for various cancers

Isis Pharmaceuticals (ISIS 3521)

RNA messenger protein that encourages cell growth, Phase 3 trials for lung cancer

Millennium Pharmaceuticals (LDP-341)

Enzyme that blocks cell death, Phase 2 trials for myeloma and leukemia

OSI, Genentech and Roche (OSI-774)

An enzyme released by the EGF receptor, Phase 2 for lung and head and neck cancers

Sugen/Pharmacia (SU5416)

Growth factor that stimulates blood vessel growth, Phase 3 trials for colon cancer


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus